One possible reason for this is that pemafibrate decreases the overexpression of urate transporter 1 and glucose transporter 9 owing to insulin resistance and improves systemic insulin resistance [17]; however, the precise mechanisms remain to be elucidated. Here, SLC22A12 is linked to Insulin resistance.